BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.91 USD | -1.53% |
|
-8.71% | -16.09% |
Presenter SpeechJoshua Schimmer (Analysts)All right. Welcome, everyone. It's Josh Schimmer fro...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
80.91
USD
Average target price
110
USD
Spread / Average Target
+35.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.09% | 15.36B | |
| -4.49% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B | |
| -6.78% | 8.12B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 01
